AR015310A1 - NEW DRUGS FROM THE POTASSIUM CHANNEL AND ITS USES - Google Patents

NEW DRUGS FROM THE POTASSIUM CHANNEL AND ITS USES

Info

Publication number
AR015310A1
AR015310A1 ARP990102703A ARP990102703A AR015310A1 AR 015310 A1 AR015310 A1 AR 015310A1 AR P990102703 A ARP990102703 A AR P990102703A AR P990102703 A ARP990102703 A AR P990102703A AR 015310 A1 AR015310 A1 AR 015310A1
Authority
AR
Argentina
Prior art keywords
channels
compounds
binders
relates
present
Prior art date
Application number
ARP990102703A
Other languages
Spanish (es)
Original Assignee
Advanced Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Medicine Inc filed Critical Advanced Medicine Inc
Publication of AR015310A1 publication Critical patent/AR015310A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Furan Compounds (AREA)

Abstract

La presente invencion se relaciona con nuevos compuestos multienlazantes que se enlazan a los canales de potasio (K+) y modulan su actividad. Loscompuestos de esta invencion comprenden ligantes de los canales 2-10 K+, covalentemente conectados por un enlazante o enlazantes, donde los ligantes ensu estado monovalente (p.e., no ligados) se enlazan y son capaces de modular la actividad de uno o más tipos de canales K+. La manera de enlazarse los ligantesen conjunto es tal que los agentesmultienlazantes así formados demuestran un efecto biologico y/o terapéutico incrementado, al ser comparado con el mismonumero de ligantes no enlazados puestos a disposicion por el enlace al canal K+. La invencion también se relaciona a los métodos de uso de tales compuestosy a los métodos de preparacion. Los compuestos de esta invencion son particularmente utiles en el tratamiento de enfermedades y condiciones demamíferos que son mediadas por los canales K+. Por consiguiente, lapresente invencion se relaciona también a composiciones farmacéuticas que comprenden unexcipiente aceptable farmacéuticamente y a una cantidad efectiva del compuesto de la presente invencion.The present invention relates to new multi-linker compounds that bind to potassium (K +) channels and modulate their activity. The compounds of this invention comprise binders of the 2-10 K + channels, covalently connected by a linker or linkers, where the binders in their monovalent state (eg, unlinked) are linked and are capable of modulating the activity of one or more types of channels K +. The way of binding the binders together is such that the multi-linking agents thus formed demonstrate an increased biological and / or therapeutic effect, when compared with the same number of unbound binders made available by the link to the K + channel. The invention also relates to the methods of use of such compounds and to the methods of preparation. The compounds of this invention are particularly useful in the treatment of diseases and conditions of mammals that are mediated by the K + channels. Accordingly, the present invention also relates to pharmaceutical compositions comprising a pharmaceutically acceptable carrier and an effective amount of the compound of the present invention.

ARP990102703A 1998-06-08 1999-06-08 NEW DRUGS FROM THE POTASSIUM CHANNEL AND ITS USES AR015310A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8846598P 1998-06-08 1998-06-08
US9306898P 1998-07-16 1998-07-16
US11386498P 1998-12-24 1998-12-24

Publications (1)

Publication Number Publication Date
AR015310A1 true AR015310A1 (en) 2001-04-18

Family

ID=27375970

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990102703A AR015310A1 (en) 1998-06-08 1999-06-08 NEW DRUGS FROM THE POTASSIUM CHANNEL AND ITS USES

Country Status (7)

Country Link
EP (1) EP1086063A1 (en)
JP (1) JP2002517466A (en)
AR (1) AR015310A1 (en)
AU (1) AU4426499A (en)
CA (1) CA2318745A1 (en)
SG (1) SG80037A1 (en)
WO (1) WO1999064050A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10019067C1 (en) * 2000-04-18 2001-10-04 Lohmann Therapie Syst Lts Transdermal plaster comprising dofetilide, is useful for treatment of cardiovascular disorders
BR0114272A (en) * 2000-09-29 2003-08-26 Solvay Pharm Bv Ionic force independent prolonged release pharmaceutical formulation
WO2002057792A2 (en) * 2000-12-29 2002-07-25 Neogenesis Pharmaceuticals, Inc. Affinity selection-based screening of hydrophobic proteins
WO2008112287A1 (en) * 2007-03-12 2008-09-18 Nektar Therapeutics Oligomer-beta blocker conjugates
KR20100135909A (en) 2008-04-17 2010-12-27 사노피-아벤티스 Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality
US8602215B2 (en) 2010-06-30 2013-12-10 Sanofi Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0510132B1 (en) * 1990-09-28 1997-05-14 Neorx Corporation Polymeric carriers for release of covalently linked agents
US5288514A (en) * 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support

Also Published As

Publication number Publication date
WO1999064050A9 (en) 2000-04-20
EP1086063A4 (en) 2001-03-28
AU4426499A (en) 1999-12-30
CA2318745A1 (en) 1999-12-16
WO1999064050A8 (en) 2000-02-24
WO1999064050A1 (en) 1999-12-16
SG80037A1 (en) 2001-04-17
EP1086063A1 (en) 2001-03-28
JP2002517466A (en) 2002-06-18

Similar Documents

Publication Publication Date Title
CR9879A (en) CCR5 MODULATORS (APPLICATION DIVISIONAL N ° 6392)
DE69737867D1 (en) TARGETED COMBINATION IMMUNOTHERAPY FOR CANCER
NO20026255L (en) Polymeric micelle compositions
MX9300298A (en) TIOETER CONJUGATES AND PROCEDURE FOR THEIR PREPARATION
DK1242401T3 (en) Cytotoxic agents comprising taxanes and their therapeutic use
BR9905977A (en) Ccr5 modulators
TR200001840T2 (en) Aryl-bound azopolyclic compounds
ECSP056256A (en) TRICYCLE DELTA-OPIOID MODULATORS
ES2168737T3 (en) INHIBITORS OF NITRICO SINTASA OXIDE.
AR010752A1 (en) COMPOUNDS WHICH BIND TO AND ACTIVATE A THROMBOPOYETINE RECEPTOR; PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, THEIR USE FOR THE PREPARATION OF MEDICINES, AND PROCESS TO PREPARE SUCH COMPOSITION.
HN1999000080A (en) ISOTIAZOL DERIVATIVES USEFUL AS ANTI-CANCER AGENTS.
DE60031793D1 (en) DOXORUBICIN AND DAUNORUBICIN-CONTAINING CYTOTOXIC AGENTS AND THEIR THERAPEUTIC USE
GT199700079A (en) TRICYCLES DERIVATIVES REPLACED WITH PHENYLAMINE
BR0010700A (en) Analog conjugates of polyamine and quinone conjugates as therapies for cancers and prostate diseases
PA8582701A1 (en) NEW OXAZOL AND TIAZOL COMPOUNDS AS INHIBITORS OF THE TRANSFORMING GROWTH FACTOR (TGF)
ES2165723T3 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING MUPIROCINE.
GT199800106A (en) AZETIDINS.
AR015310A1 (en) NEW DRUGS FROM THE POTASSIUM CHANNEL AND ITS USES
PL346019A1 (en) Nimesulide containing topical pharmaceutical compositions
BR0112807A (en) Indole derivatives and their application as a medicine
UY26877A1 (en) PIRAZOL-TIAZOL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, AND ITS INSTRUCTIONS FOR INHIBITING CYCLINE-DEPENDENT KINASES
ECSP993000A (en) NEW DRUGS OF THE POTASSIUM CHANNEL AND ITS USES
ATE331730T1 (en) NEW DEPSIPEPTIDE COMPOUND
ES2161913T3 (en) TRINUCLEAR CATIONIC COMPLEXES OF PLATINO THAT HAVE AN ANTITUMORAL ACTIVITY AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
ECSP993298A (en) CCR5 MODULATORS